JDP Therapeutics Inc., a Blue Bell, PA-based specialty pharmaceutical company, secured up to $17m Series A equity financing.
The round was led by China based CoSci Med-Tech Co., Ltd.
Led by Jie Du, Ph.D., CEO and president, JDP Therapeutics is advancing JDP-205, a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market.
The company intends to use the funds to advance JDP-205 through its pivotal phase III clinical trial, NDA filing and approval. Prior to this round of financing, JDP-205 had completed phase I and II clinical trials, an end-of-phase-II FDA meeting, and FDA agreement on its pivotal phase III clinical protocol.
JDP Therapeutics has also secured a commercial supply agreement for its JDP-205 product with a major pharmaceutical company.